Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®

Dokument -

Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®

Isofol Medical, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment to support the clinical program with Modufolin®, Isofol’s lead drug candidate. Modufolin® is a novel folate-based compound being developed to increase the efficacy and reduce the side effects of chemotherapeutic agents used in the treatment of solid tumors.
  • Licens: All rights reserved
    Innehållet får bara användas av Mynewsdesk. Det är alltså inte tillåtet för någon annan att ladda ner, kopiera, sprida eller på annat sätt använda Innehållet (annat än för privat bruk i den mån det följer av lag).
  • Filformat: .pdf

Kontakter

Anders Rabbe

Presskontakt CEO +46 (0)707 646 500

Jan-Eric Österlund

Presskontakt Executive Chairman + 44 7785 368155

Relaterat innehåll

Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®

Isofol Medical, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment to support the clinical program with Modufolin®, Isofol’s lead drug candidate. Modufolin® is a novel folate-based compound being developed to increase the efficacy and reduce the side effects of chemotherapeutic agents used in the treatment of solid tumors.